Ge Healthcare Technologies Inc Stock

GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for its positron emission tomography (PET) imaging agent Vizamyl^TM

GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for clinicians now recommend considering fluoroestradiol (FES) positron

GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company’s Optison™ (Perflutren Protein-Type A Microspheres

GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility

GE HealthCare’s commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week’s Society of Nuclear Medicine and Molecular

At this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of

Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development

GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare’s proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver

GE HealthCare (Nasdaq: GEHC) today announced the launch of CleaRecon DL, technology powered by a deep-learning algorithm, to improve the quality of cone-beam computed tomography (CBCT) images. This

GE HealthCare (Nasdaq: GEHC) and Raydiant Oximetry, Inc. today announced a joint development initiative to enhance fetal monitoring capabilities that could strengthen the support of clinical

GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA™ Sprint, an FDA 510(k) pending¹ ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic

GE HealthCare (Nasdaq: GEHC) today announced an intended expansion of its radiation oncology portfolio as well as the introduction of the new AI-enabled MR Contour DL™ at the European Society for

GE HealthCare (Nasdaq: GEHC) today reported financial results for the first quarter ended March 31, 2025.

GE HealthCare President and CEO Peter Arduini said, “First quarter results reflect strong

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.

• 
  Bank of America Securities Healthcare Conference in

GE HealthCare (Nasdaq: GEHC), a global leader in breast health technology, will feature its latest advancements in diagnostic accuracy and patient-centered breast care during the 2025 Society of

GE HealthCare (Nasdaq: GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a

Cincinnati Children’s and GE HealthCare (Nasdaq: GEHC) will form a strategic research program focused on driving clinical and technical research to advance innovation for pediatric care delivery

GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025.

At the American College of Cardiology 2025 meeting, GE HealthCare (Nasdaq: GEHC) will proudly introduce Revolution™ Vibe,ⁱ a new computed tomography (CT) system with Unlimited One-Beat Cardiac

The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to

GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo, taking

GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative

GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous

GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience